Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Recent Advances on Innovative Radiopharmaceuticals in Preclinical and Clinical Cancer...
share announcement

Recent Advances on Innovative Radiopharmaceuticals in Preclinical and Clinical Cancer Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 4094

Special Issue Editors

Dr. Désirée Déandréis

E-Mail Website
Guest Editor
Department of Medical Imaging, Institut Gustave Roussy, Villejuif, France
Interests: cancer nuclear medicine for diagnosis and therapeutics
Dr. Roberto Passera

E-Mail Website
Guest Editor
Department of Medical Sciences, University of Torino, 10126 Turin, Italy
Interests: biostatistics; radiochemistry; pharmacokinetics; clinical pharmacy, radiopharmacy; clinical epidemiology

Special Issue Information

Dear Colleagues,

Recently, nuclear medicine has gained a crucial role in cancer characterization, staging, restaging and follow-up, either for solid tumors or oncohematologic ones. Moreover, very recently, the field of interest for nuclear medicine been has further extended to include cancer therapy too, mainly peptide receptor radionuclide therapy (PRRT).

We are pleased to invite you to submit your contributions dedicated to advances in cancer preclinical and clinical nuclear medicine, focusing either on new diagnostic molecules and procedures or recent therapeutic applications.

This Special Issue aims to investigate the use of innovative radiopharmaceuticals and novel technological applications in the field of positron emission tomography (PET) diagnostic imaging, such as PET/computed tomography (CT), PET/magnetic resonance imaging (MRI), and molecular radiotherapy in oncology. The invited contributions should improve knowledge regarding the in vivo characterization of cancer biological processes, forming the basis for the predictive and prognostic role of molecular imaging and allowing for more personalized treatments based on specific molecular targeting.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) preclinical research and clinical trials on new cancer radiopharmaceuticals.

We look forward to receiving your contributions.

Dr. Désirée Déandréis
Dr. Roberto Passera
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nuclear medicine
  • radiopharmaceutical
  • PET-CT
  • clinical trial
  • preclinical trial
  • cancer
  • clinical oncology
  • solid tumors
  • oncohematology
  • PRRT
  • urologic oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 293 KiB  
Review
Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective
by Francesco Mattana, Lorenzo Muraglia, Antonio Barone, Marzia Colandrea, Yasmina Saker Diffalah, Silvia Provera, Alfio Severino Cascio, Emanuela Omodeo Salè and Francesco Ceci
Cancers 2024, 16(9), 1643; https://doi.org/10.3390/cancers16091643 - 25 Apr 2024
Cited by 6 | Viewed by 3184
Abstract
In the last decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of prostate cancer (PCa) patients thanks to its higher diagnostic accuracy in comparison with conventional imaging both in staging and in recurrence. Alongside molecular imaging, [...] Read more.
In the last decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of prostate cancer (PCa) patients thanks to its higher diagnostic accuracy in comparison with conventional imaging both in staging and in recurrence. Alongside molecular imaging, PSMA was studied as a therapeutic agent targeted with various isotopes. In 2021, results from the VISION trial led to the Food and Drug Administration (FDA) approval of [177Lu]Lu-PSMA-617 as a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) and set the basis for a radical change in the future perspectives of PCa treatment and the history of Nuclear Medicine. Despite these promising results, primary resistance in patients treated with single-agent [177Lu]Lu-PSMA-617 remains a real issue. Emerging trials are investigating the use of [177Lu]Lu-PSMA-617 in combination with other PCa therapies in order to cover the multiple oncologic resistance pathways and to overcome tumor heterogeneity. In this review, our aim is to retrace the history of PSMA-targeted therapy from the first preclinical studies to its future applications in PCa. Full article
(This article belongs to the Special Issue Recent Advances on Innovative Radiopharmaceuticals in Preclinical and Clinical Cancer Research)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop